Molecular characterization of prostate cancer

Severson TM, Minnee E, Zhu Y, Schuurman K, Nguyen HM, Brown LG, Hakkola S, Menezes R, Gregoricchio S, Kim Y, Kneppers J, Linder S, Stelloo S, Lieftink C, van der Heijden MS, Nykter M, van der Noort V, Sanders J, Morris B, Jenster G, van Leenders GJ, Pomerantz M, Freedman ML, Beijersbergen RL, Urbanucci A et al. (2025)
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer
Cell Rep Med, 102215 (in press)
DOI 10.1016/j.xcrm.2025.102215, PubMed 40609538

Kiviaho A, Eerola SK, Kallio HML, Andersen MK, Hoikka M, Tiihonen AM, Salonen I, Spotbeen X, Giesen A, Parker CTA, Taavitsainen S, Hantula O, Marttinen M, Hermelo I, Ismail M, Midtbust E, Wess M, Devlies W, Sharma A, Krossa S, Häkkinen T, Afyounian E, Vandereyken K, Kint S, Kesseli J et al. (2024)
Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer
Nat Commun, 15 (1), 9949
DOI 10.1038/s41467-024-54364-1, PubMed 39550375

Bischof K, Cremaschi A, Eroukhmanoff L, Landskron J, Flage-Larsen LL, Gade A, Bjørge L, Urbanucci A, Taskén K (2024)
Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways
Mol Oncol, 19 (1), 81-98
DOI 10.1002/1878-0261.13726, PubMed 39245677